Tan, Shuk Kuen Sandy Tang, Man Choi Wan, Ching Han Wong, Kong Chiu Wong, Shiu Man, Pui Yan Wong, Jude Wong, Woon Sing Raymond Wong, Wai Shan Sandy Woo, Kit Yu Young, Cheuk Wan Yim, Ka Lung Carrel Yu, and Ka Yan Catherine Yuen, Ka Man Amy Yung. “
“To evaluate the prevalence and diagnostic significance of the autoantibody against citrullinated vimentin (anti-Sa) compared with the widely used anti-cyclic citrullinated peptide autoantibody

(anti-CCP) in patients with rheumatoid arthritis (RA). One hundred and sixty-nine patients hospitalized at the Department of Rheumatology and Internal Medicine, Poznan University of Medical Sciences, Poznań, Poland, check details were enrolled in a cross-sectional study and divided into two groups. The RA group comprised 41 patients diagnosed as having RA. The non-RA control group included 128 individuals with a Alectinib variety of rheumatic disorders. Serum anti-Sa and anti-CCP measurements were performed

by enzyme-linked immunosorbent assay. The sensitivity and specificity of anti-Sa for the diagnosis of RA was 36.6% and 96.9%, respectively. For the anti-CCP test, the sensitivity was 65.9% and the specificity was 95.3%. Concomitant presence of anti-Sa and anti-CCP was determined in 36.6% of the patients with RA, whereas isolated positivity of anti-Sa was not observed. Anti-Sa positive RA patients had significantly higher anti-CCP levels compared to anti-Sa negative subjects (P < 0.05). With regard to the relatively low diagnostic sensitivity and the

lack of cases identified by anti-Sa alone, we were unable to demonstrate Loperamide any additional diagnostic value of the anti-Sa autoantibody in comparison to the anti-CCP autoantibody. To the authors’ best knowledge, this is the first study among Polish patients verifying the clinical utility of anti-Sa in the diagnosis of RA. “
“Patients with rheumatoid arthritis (RA) are at significantly higher risk of cardiovascular (CV) morbidity and mortality compared with the general population. Traditional CV risk factors cannot explain the total excess of CV morbidity and mortality in RA patients. At present, it is not clear whether treatment with statins might be of benefit in RA patients. The aim of the present systematic literature review is to summarize the published evidence concerning treatment with statins and its impact on CV events in RA patients. A systematic literature review of studies on RA and statins was carried out in the database PubMed. Search terms were ‘simvastatin OR atorvastatin OR fluvastatin OR lovastatin OR pravastatin OR rosuvastatin OR statin AND arthritis’.